Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment for patients aged 12 or older after complete resection of stage IIB or IIC melanoma.
LAMPGEN ANALYSIS
Why it matters
The adjuvant indication moved to a node-negative, higher-risk stage group.
What research teams should watch
Verify pathologic stage, resection status and age before applying the label.
PRIMARY RECORDS